KR20190045271A - nNIF 및 nNIF-관련된 펩타이드 및 관련된 방법 - Google Patents

nNIF 및 nNIF-관련된 펩타이드 및 관련된 방법 Download PDF

Info

Publication number
KR20190045271A
KR20190045271A KR1020197009122A KR20197009122A KR20190045271A KR 20190045271 A KR20190045271 A KR 20190045271A KR 1020197009122 A KR1020197009122 A KR 1020197009122A KR 20197009122 A KR20197009122 A KR 20197009122A KR 20190045271 A KR20190045271 A KR 20190045271A
Authority
KR
South Korea
Prior art keywords
nnif
nrp
seq
net
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197009122A
Other languages
English (en)
Korean (ko)
Inventor
크리스천 콘 요스트
가이 에이. 지머맨
앤드류 에스. 웨이리치
조슈아 쉬프만
Original Assignee
더 유니버시티 오브 유타 리서치 파운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 유니버시티 오브 유타 리서치 파운데이션 filed Critical 더 유니버시티 오브 유타 리서치 파운데이션
Publication of KR20190045271A publication Critical patent/KR20190045271A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020197009122A 2016-09-02 2017-09-05 nNIF 및 nNIF-관련된 펩타이드 및 관련된 방법 Ceased KR20190045271A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662383243P 2016-09-02 2016-09-02
US62/383,243 2016-09-02
US201762492019P 2017-04-28 2017-04-28
US62/492,019 2017-04-28
PCT/US2017/050072 WO2018045371A2 (en) 2016-09-02 2017-09-05 nNIF AND nNIF-RELATED PEPTIDES AND RELATED METHODS

Publications (1)

Publication Number Publication Date
KR20190045271A true KR20190045271A (ko) 2019-05-02

Family

ID=61309026

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197009122A Ceased KR20190045271A (ko) 2016-09-02 2017-09-05 nNIF 및 nNIF-관련된 펩타이드 및 관련된 방법

Country Status (13)

Country Link
US (1) US10857201B2 (https=)
EP (1) EP3506924A4 (https=)
JP (1) JP2019534247A (https=)
KR (1) KR20190045271A (https=)
CN (1) CN109937047A (https=)
AU (1) AU2017321965A1 (https=)
BR (1) BR112019004299A2 (https=)
CA (1) CA3035770A1 (https=)
MX (1) MX2019002479A (https=)
RU (1) RU2019109049A (https=)
SG (1) SG11201901830UA (https=)
WO (1) WO2018045371A2 (https=)
ZA (1) ZA201901942B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11324801B2 (en) 2016-09-02 2022-05-10 University Of Utah Research Foundation NNIF and nNIF-related peptides and related methods
US20230158108A1 (en) * 2020-05-04 2023-05-25 University Of Utah Research Foundation Immunothrombosis in covid-19 acute respiratory distress syndrome
CN117004744B (zh) * 2022-04-27 2024-05-24 数字碱基(南京)科技有限公司 一种基于血浆微生物dna特征的肺癌预后评估方法及模型

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799766B2 (en) * 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US9308235B2 (en) * 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
EP4219534A3 (en) * 2013-07-08 2023-09-27 The University of Utah Research Foundation Methods for treatment of and prophylaxis against inflammatory disorders

Also Published As

Publication number Publication date
JP2019534247A (ja) 2019-11-28
EP3506924A2 (en) 2019-07-10
CA3035770A1 (en) 2018-03-08
RU2019109049A3 (https=) 2020-12-24
US10857201B2 (en) 2020-12-08
EP3506924A4 (en) 2020-05-20
ZA201901942B (en) 2020-10-28
MX2019002479A (es) 2019-09-19
WO2018045371A2 (en) 2018-03-08
BR112019004299A2 (pt) 2019-05-28
SG11201901830UA (en) 2019-03-28
RU2019109049A (ru) 2020-10-05
US20190201487A1 (en) 2019-07-04
WO2018045371A3 (en) 2018-04-12
CN109937047A (zh) 2019-06-25
AU2017321965A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
Yost et al. Neonatal NET-inhibitory factor and related peptides inhibit neutrophil extracellular trap formation
US11752203B2 (en) Methods for treatment of and prophylaxis against inflammatory disorders
EP2209485B1 (en) Extracellular histones as biomarkers for prognosis and molecular targets for therapy
Seeliger et al. Expression of calcium-binding proteins MRP8 and MRP14 in inflammatory muscle diseases
US8304389B2 (en) Methods of inhibiting cell death or inflammation in a mammal by administering a BCL protein
US10857201B2 (en) NNIF and nNIF-related peptides and related methods
EP3724215B1 (en) Peptidomimetics, method of synthesis and uses thereof
AU2019240693A1 (en) Kv1.3 potassium channel antagonists
WO2007085057A1 (en) A medical protocol
US11324801B2 (en) NNIF and nNIF-related peptides and related methods
JPH08504085A (ja) リポ多糖体結合及び抗擬血活性をもつ哺乳動物のカチオン性タンパク質
AU2003282027B2 (en) Method for determining the susceptibility of a subject to infection
HK40004861A (zh) Nnif和nnif相关肽以及相关方法
US20250122265A1 (en) Recombinant human cd5l protein, active fragments or peptides derived thereof and pharmaceutical composition comprising the recombinant human cd5l protein, active fragments or peptides derived thereof for the treatment of acute infectious diseases,inflammatory diseases and sepsis
Zhang IL-22 Binding Protein (IL22BP) Prevents Non-Canonical IL-22 Signaling and Reduces Bleomycin Induced Acute Lung Injury
JP4913742B2 (ja) 方法及び手段
WO2018224548A1 (en) Point-of-care testing of pro-thymosin 100-109 for detecting sepsis
Chernyaeva et al. Reduced Binding of Apolipoprotein E4 Isoform to Complement Factor H Promotes Amyloid-Β Induced Neuroinflammation in vitro and in vivo

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190329

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200901

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220629

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230328

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220629

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I